The CIRG team are excited to start recruiting to two new studies into innovative new treatments.

The EAGLE-1 study will compare the efficacy and safety of gepotidacin to intramuscular ceftriaxone plus oral azithromycin in patients with uncomplicated gonorrhoea caused by the bacterium NG. Gepotidacin (GSK2140944) is the first in a new class of antibiotics, called triazaacenaphthylene topoisomerase inhibitors, developed at GSK in 2007 with a novel “dual targeting” mechanism of action (MOA) and oral formulation. Its MOA is distinct from any currently approved antibiotic.

The RIO study will trial a combination of the two long-acting broadly neutralising antibodies, 3BNC117-LS and 10-1074-LS. It is hypothesised that these recently developed bNAbs will induce a period of virological remission even when when ART is stopped. The combination of 3BNC117 and 10-1074 has already been tested in humans in a single-arm proof of principle study that suggested that this combination can impose full, sustained viral suppression in the absence of ART. The bNAbs will now be tested in a randomised clinical trial powered to answer the question of whether these they are effective at controlling HIV replication in the absence of ART.